IP Library Granted Patent US 7,045,350
Granted Patent B2
US 7,045,350 · App. 10/230,839 · Granted May 16, 2006

Alternatively spliced circulating tissue factor

Assignee: Mount Sinai School of Medicine of New York University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,045,350
App. No.
10/230,839
Granted
May 16, 2006
Kind
B2
Abstract

A new circulating form of soluble human tissue factor was identified. This new form of human tissue factor appears to be the result of alternative splicing and is therefore referred to as “alt-hTF.” Alt-hTF mRNA was detected in a cell line, HL-60. The cDNA region encoding the entire open reading frame of alt-hTF was cloned. The sequence encoding the alt-hTF mature peptide was expressed in bacteria. alt-hTF consists of the first 166 amino acids of membrane bound TF, and a 40 amino acid C-terminal region unique to alt-hTF. Alt-hTF is likely to be a useful target for compounds to inhibit clotting and to treat disorders associated with elevated TF. It may also be useful as a target for antibodies selectively reactive with alt-hTF, to remove it from the circulation for treatment of clotting or other disorders associated with elevated or abnormal levels of TF, including thrombotic conditions, cardiovascular disorders, DVT, DIC, and possibly metastatic cancers.

Claims (15)

1. An isolated alternatively spliced form of human tissue factor.

2. The tissue factor of claim 1 comprising Y S T S L E L W Y L W S S S L S S S W L Y L Y T S V E R Q E W G R A G R R T P H (SEQ ID NO:1).

3. The tissue factor of claim 1 comprising conservative amino acid substitutions.

4. An isolated human tissue factor protein comprising the sequence serine-serine-serine-leucine-serine-serine-serine (SEQ ID NO: 4).

5. The protein of claim 4 wherein the serines point outward having a high dielectric constant.

6. The protein of claim 4 wherein the serines point inward having a low dielectric constant.

7. An isolated nucleotide molecule encoding the tissue factor protein of claim 1 .

8. The nucleotide molecule of claim 7 in a vector for expression of the tissue factor protein.

9. The nucleotide molecule of claim 8 in a vector for expression in a bacterial host.

10. The nucleotide molecule of claim 8 in a vector for expression in a eukaryotic host cell.

11. A method for making the tissue factor protein of claim 1 comprising expressing the nucleotide molecule of claim 8 in a suitable host cell in cell conditions permitting expression of the tissue factor protein and isolating the tissue factor protein therefrom.

12. An isolated double stranded RNA molecule comprising mRNA encoding the tissue factor protein of claim 1 .

13. An isolated antibody that is specifically immunoreactive with the tissue factor protein of claim 1 .

14. The antibody of claim 13 conjugated to a detectable label.

15. The antibody of claim 13 immobilized to a column or filter.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 7, 2016
From: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039276/0270 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2002
From: NEMERSON, YALE; BOGDANOV, VLADIMIR
To: MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY
Reel/Frame 013254/0206 →
Continuity (2)
Provisional Application 6031624400 · Aug 30, 2001
Related Publication 20030049784A1 · Mar 13, 2003